| 2024-11-27: Table 2 fallacy | link | |
| 2024-10-19: Joint PSI/EFSPI Causal Inference SIG Webinar: Opportunities in applying a causal inference framework during the analysis of an RCT | link | |
| 2024-10-03: Considerations for the planning, conduct and reporting of clinical trials with interim analyses | link | code | |
| 2024-09-30: How to deal with a contaminated analysis set? | link | |
| 2024-09-22: What is your intention behind using “intention-to-treat”? | link | |
| 2024-09-02: Drug developers quiz! | link | |
| 2024-08-29: Quote from 1984 about historical controls | link | |
| 2024-08-05: Embed investigator- and independently reviewed PFS into the estimand framework | link | |
| 2024-07-31: Kaspar to leave Roche | link | |
| 2024-07-17: Efficient estimation in subgroups in RCTs | link | |
| 2024-07-09: Non-proportional hazards in drug development: Part 2 | link | |
| 2024-06-30: Non-proportional hazards in drug development | link | |
| 2024-05-31: SAVVY overview paper with recommendations on updates of safety guidelines | link | |
| 2024-03-06: False negative risk of futility analyses is typically overestimated | link | code | |
| 2024-03-01: Why and what a non-statistician should know about causal inference | link | |
| 2023-11-10: Implementation of statistical innovation in a pharmaceutical company | link | |
| 2023-10-13: Futility analyses – they are a strategic tool in drug development and not at all futile! | link | |
| 2023-10-12: Crossover in oncology trials - presentation at FDA / Lungevity statistical forum | link | |
| 2023-08-09: Minimal detectable difference in a trial with time-to-event primary endpoint | link | code | |
| 2023-08-05: Discussion of JSM session “Recent advances in Bayesian power and probability of success”, providing punch lines of my talk on quantitative decision-making | link | |
| 2023-07-12: Statistical Methodology Leaders in Drug Development | link | |
| 2023-07-06: Summary of talk at BBS next generation event | link | |
| 2023-07-05: Effective statistician podcast on driving statistical innovation | link | |
| 2023-06-06: Why can’t we simply get rid of RCTs? | link | |
| 2023-06-05: Why do we randomize in RCTs? | link | |
| 2023-04-02: Why do we do interim analyses in clinical trials? | link | |
| 2023-03-29: Quantification of follow-up | link | |
| 2023-03-07: How can the estimands addendum framework be “married” with competing risks? | link | |
| 2023-02-02: Trial design using multistate modelling for PFS and OS | link | |
| 2023-01-04: Estimation of AE risk in RCTs | link | |
| 2022-12-02: Are regulators on board with estimands? | link | |
| 2022-05-01: Thoughts on my 10th year anniversary at Roche | link | |
| 2022-02-09: Academia - Industry collaboration award of Ulm University for Roche’s long-term collaboration with Jan Beyersmann | link | |